Global Gastric Electric Stimulation (GES) Devices Market Size By Type (Low Frequency GES Device, High Frequency GES Device), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023...

The Global Gastric Electric Stimulation (GES) Devices Market was valued at USD 412 million in 2023 and is expected to surpass USD 793 million by 2031, expanding at a CAGR of 8.4% during the forecast period (2023–2031). GES devices are increasingly being adopted to manage chronic gastrointestinal disorders such as gastroparesis and obesity, offering an effective alternative for patients unresponsive to pharmacological therapies. The market growth is being propelled by advancements in neurostimulation technologies, rising prevalence of functional gastrointestinal disorders, and the growing preference for minimally invasive treatments.

Drivers:

1. Rising Prevalence of Gastroparesis and Obesity:

An increasing number of patients suffering from chronic gastroparesis, often linked to diabetes, and obesity-related gastrointestinal issues is driving demand for GES devices globally.

2. Technological Advancements in Neurostimulation:

Modern GES devices offer improved battery life, programmable stimulation parameters, and wireless remote monitoring, which enhances both physician and patient experience.

3. Increasing Demand for Minimally Invasive Therapies:

GES provides a less invasive alternative compared to surgeries like gastric bypass, contributing to growing adoption in both developed and emerging markets.

Restraints:

1. High Cost and Limited Reimbursement:

GES device implantation and maintenance involve significant costs. Combined with limited insurance coverage in some regions, this presents a barrier to widespread adoption.

2. Inconsistent Clinical Efficacy:

Variability in treatment outcomes for patients, along with the absence of clear universal guidelines for patient selection, hinders broader clinical acceptance.

Opportunity:

1. Emerging Markets and Untapped Populations:

Rapid healthcare infrastructure development in Asia-Pacific and Latin America provides lucrative opportunities for market expansion, particularly where obesity and diabetes prevalence is on the rise.

2. Integration of Smart Features in GES Devices:

Incorporating AI and IoT capabilities for real-time data monitoring, remote diagnostics, and personalized treatment can revolutionize patient care and expand the utility of GES systems.

Market by System Type Insights:

In 2023, the implantable GES devices segment dominated the market, driven by their effectiveness in long-term treatment of gastroparesis and regulatory approval across key regions. However, external stimulation systems are gaining traction due to ease of use, lower costs, and fewer surgical risks, and are expected to witness the highest growth rate during the forecast period.

Market by End-use Insights:

The hospitals and specialty clinics segment held the largest market share in 2023, attributed to the availability of advanced surgical infrastructure and expertise. Meanwhile, the ambulatory surgical centers (ASCs) segment is projected to grow significantly due to increasing preference for outpatient procedures and cost-efficiency.

Market by Regional Insights:

North America dominated the global GES devices market in 2023, fueled by high awareness, strong healthcare infrastructure, and favorable reimbursement policies. However, Asia-Pacific is anticipated to register the highest CAGR through 2031, driven by rising incidences of obesity, diabetic gastroparesis, and increasing healthcare investments in nations such as China and India.

Competitive Scenario:

Key market players include Medtronic plc, EnteroMedics Inc. (now ReShape Lifesciences), IntraPace, Inc., and NeuroPace, Inc. These companies focus on product innovation, regulatory approvals, and strategic collaborations to strengthen their market footprint.

Key Developments:

In 2023, Medtronic launched an updated version of its GES system with enhanced battery life and wireless control features.

ReShape Lifesciences expanded its distribution network across Asia-Pacific in 2024, aiming to capitalize on rising demand in emerging markets.

In 2025, IntraPace received CE mark approval for its new external GES system designed for outpatient monitoring.

Scope of Work – Global Gastric Electric Stimulation (GES) Devices Market

Report Metric Details

Market Size (2023) USD 412 million

Projected Market Size (2031) USD 793 million

CAGR (2023–2031) 8.4%

Key Segments System Type (Implantable, External), End-use

Growth Drivers Rising gastroparesis and obesity rates, technological advancements

Opportunities Emerging markets, AI-integrated smart GES devices

FAQs:

1) What is the current market size of the Global Gastric Electric Stimulation (GES) Devices Market?

The market was valued at USD 412 million in 2023.

2) What is the major growth driver of the Global Gastric Electric Stimulation (GES) Devices Market?

The increasing prevalence of chronic gastroparesis and obesity, along with technological advancements in neurostimulation.

3) Which is the largest region during the forecast period in the Global Gastric Electric Stimulation (GES) Devices Market?

North America holds the largest market share, but Asia-Pacific is expected to witness the highest growth.

4) Which segment accounted for the largest market share in the Global Gastric Electric Stimulation (GES) Devices Market?

The implantable GES devices segment dominated in 2023.

5) Who are the key market players in the Global Gastric Electric Stimulation (GES) Devices Market?

Medtronic plc, ReShape Lifesciences, IntraPace, Inc., and NeuroPace, Inc. are among the major players.